Well Referenced

Tag: Acetyl-L-carnitine

“Brain-specific” nutrients: a memory cure?

This 2003 review critically evaluates the efficacy of several nonprescription compounds marketed as memory enhancers, including phosphatidylserine (PS), phosphatidylcholine (PC), citicoline, piracetam, vinpocetine, acetyl-L-carnitine (ALC), and antioxidants like vitamin E. While animal studies suggest potential cognitive benefits, human clinical trials yield inconsistent and modest results. For instance, PS shows limited

Read More »
June 26, 2025 No Comments

L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain

This review article examines the neuroprotective roles of L-carnitine and its acetylated derivative, acetyl-L-carnitine (ALCAR), in the developing brain. L-carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, crucial for energy production. ALCAR, capable of crossing the blood-brain barrier, provides acetyl groups for acetylcholine synthesis and supports

Read More »
June 26, 2025 No Comments

A Review of Alternative Treatment Options in Diabetic Polyneuropathy

This 2021 narrative review evaluates non-conventional treatment modalities for diabetic polyneuropathy (DPN), a common yet difficult-to-treat diabetes complication. It discusses pharmacologic and non-pharmacologic alternatives such as topical agents (capsaicin, lidocaine), nutritional supplements (alpha-lipoic acid, benfotiamine, acetyl-L-carnitine), and non-invasive modalities (acupuncture, electrical nerve stimulation). While several of these interventions demonstrated symptom

Read More »
June 26, 2025 No Comments

Natural products – alpha-lipoic acid and acetyl-L-carnitine – in the treatment of chemotherapy-induced peripheral neuropathy

This 2018 review examines the potential of alpha-lipoic acid (ALA) and acetyl-L-carnitine (ALC) in managing chemotherapy-induced peripheral neuropathy (CIPN). ALA’s antioxidant and anti-inflammatory properties have shown promise in preclinical studies, but clinical trials yield mixed results, with efficacy influenced by administration routes. ALC demonstrates benefits in vitro and in animal

Read More »
June 26, 2025 No Comments

Impaired Nicotinamide Adenine Dinucleotide (NAD⁺) Metabolism in Diabetes and Diabetic Tissues: Implications for Nicotinamide-Related Compound Treatment

This 2020 review explores how diabetes disrupts NAD⁺ metabolism, leading to reduced NAD⁺/NADH ratios (pseudohypoxia) due to increased substrate oxidation. In type 1 diabetes, NAD⁺ depletion is driven by poly(ADP-ribose) polymerase (PARP) activation, while in type 2 diabetes, decreased AMP-activated protein kinase (AMPK) activity impairs NAD⁺ biosynthesis via downregulation of

Read More »
June 26, 2025 No Comments

Management of the aging risk factor for Parkinson’s disease

This 2014 review published in Neurobiology of Aging (DOI: 10.1016/j.neurobiolaging.2013.10.073, PMID: 24246717) explores how aging—a primary risk factor for Parkinson’s disease (PD)—can be managed through targeted nutritional compounds, including alpha-lipoic acid, acetyl-L-carnitine, coenzyme Q10, and melatonin. These agents support mitochondrial energy metabolism, enhance antioxidant defenses, and modulate gene expression via

Read More »
June 26, 2025 No Comments

Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue

This study explored the effects of acetyl-L-carnitine (1 g twice daily for 24 weeks) on insulin sensitivity and glucose tolerance in 32 nondiabetic individuals at increased cardiovascular risk. Participants were divided based on their glucose disposal rate (GDR) into two groups: ≤7.9 mg/kg/min and >7.9 mg/kg/min. Significant improvements in GDR

Read More »
June 26, 2025 No Comments

Acetyl-L-carnitine for dementia

This systematic review and meta-analysis evaluated the effects of acetyl-L-carnitine (ALC) on cognitive performance in patients with mild cognitive impairment (MCI) and mild to moderate Alzheimer’s disease (AD). The analysis of randomized controlled trials showed a statistically significant benefit of ALC over placebo in cognitive assessments and clinical impression scales,

Read More »
June 26, 2025 No Comments

Double-blind, multicenter trial comparing acetyl l- carnitine with placebo in the treatment of fibromyalgia patients

This randomized controlled trial evaluated the efficacy of acetyl l-carnitine (LAC) in treating fibromyalgia syndrome (FMS) compared to placebo in 102 patients. The study involved an initial two-week intramuscular LAC administration (500 mg/day), followed by oral supplementation (1,500 mg/day) for eight weeks. Results showed significant improvements in pain reduction, depression,

Read More »
June 26, 2025 No Comments